Previous close | 3.7900 |
Open | 3.7800 |
Bid | 3.6500 x 100 |
Ask | 3.7500 x 100 |
Day's range | 3.6100 - 3.9000 |
52-week range | 1.2500 - 4.6500 |
Volume | |
Avg. volume | 297,450 |
Market cap | 277.891M |
Beta (5Y monthly) | 1.99 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0700 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.47 |
ChromaDex Corporation ( NASDAQ:CDXC ), might not be a large cap stock, but it led the NASDAQCM gainers with a...
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LOS ANGELES, March 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN